227 related articles for article (PubMed ID: 25889313)
1. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer.
Peng X; Wang P; Li S; Zhang G; Hu S
World J Surg Oncol; 2015 Feb; 13():50. PubMed ID: 25889313
[TBL] [Abstract][Full Text] [Related]
2. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial.
Ripamonti C; Mercadante S; Groff L; Zecca E; De Conno F; Casuccio A
J Pain Symptom Manage; 2000 Jan; 19(1):23-34. PubMed ID: 10687323
[TBL] [Abstract][Full Text] [Related]
3. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction.
Mercadante S; Ripamonti C; Casuccio A; Zecca E; Groff L
Support Care Cancer; 2000 May; 8(3):188-91. PubMed ID: 10789958
[TBL] [Abstract][Full Text] [Related]
4. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial.
Mystakidou K; Tsilika E; Kalaidopoulou O; Chondros K; Georgaki S; Papadimitriou L
Anticancer Res; 2002; 22(2B):1187-92. PubMed ID: 12168923
[TBL] [Abstract][Full Text] [Related]
5. Sustained release octreotide may have a role in the treatment of malignant bowel obstruction.
Massacesi C; Galeazzi G
Palliat Med; 2006 Oct; 20(7):715-6. PubMed ID: 17060271
[TBL] [Abstract][Full Text] [Related]
6. Octreotide in the management of bowel obstruction in terminal ovarian cancer.
Mangili G; Franchi M; Mariani A; Zanaboni F; Rabaiotti E; Frigerio L; Bolis PF; Ferrari A
Gynecol Oncol; 1996 Jun; 61(3):345-8. PubMed ID: 8641613
[TBL] [Abstract][Full Text] [Related]
7. Scopolamine butylbromide plus octreotide in unresponsive bowel obstruction.
Mercadante S
J Pain Symptom Manage; 1998 Nov; 16(5):278-80. PubMed ID: 9846021
[No Abstract] [Full Text] [Related]
8. A prospective study on the efficacy of octreotide in the management of malignant bowel obstruction in gynecologic cancer.
Watari H; Hosaka M; Wakui Y; Nomura E; Hareyama H; Tanuma F; Hattori R; Azuma M; Kato H; Takeda N; Ariga S; Sakuragi N
Int J Gynecol Cancer; 2012 May; 22(4):692-6. PubMed ID: 22343971
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of palliative treatment using octreotide for inoperable malignant bowel obstruction caused by advanced urological cancer.
Kubota H; Taguchi K; Kobayashi D; Naruyama H; Hirose M; Fukuta K; Kubota Y; Yasui T; Yamada Y; Kohri K
Asian Pac J Cancer Prev; 2013; 14(12):7107-10. PubMed ID: 24460259
[TBL] [Abstract][Full Text] [Related]
10. Octreotide for malignant bowel obstruction: twenty years after.
Mercadante S; Porzio G
Crit Rev Oncol Hematol; 2012 Sep; 83(3):388-92. PubMed ID: 22277783
[TBL] [Abstract][Full Text] [Related]
11. SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction.
Laval G; Rousselot H; Toussaint-Martel S; Mayer F; Terrebonne E; François E; Brixi H; Nguyen T; Bourdeix I; Bisot-Locard S; Zelek L;
Bull Cancer; 2012 Feb; 99(2):E1-9. PubMed ID: 22265994
[TBL] [Abstract][Full Text] [Related]
12. The role of somatostatin and octreotide in bowel obstruction: pre-clinical and clinical results.
Ripamonti C; Panzeri C; Groff L; Galeazzi G; Boffi R
Tumori; 2001; 87(1):1-9. PubMed ID: 11669548
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction.
Shima Y; Ohtsu A; Shirao K; Sasaki Y
Jpn J Clin Oncol; 2008 May; 38(5):354-9. PubMed ID: 18490369
[TBL] [Abstract][Full Text] [Related]
14. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction.
Hisanaga T; Shinjo T; Morita T; Nakajima N; Ikenaga M; Tanimizu M; Kizawa Y; Maeno T; Shima Y; Hyodo I
Jpn J Clin Oncol; 2010 Aug; 40(8):739-45. PubMed ID: 20410056
[TBL] [Abstract][Full Text] [Related]
15. The management of inoperable gastrointestinal obstruction in terminal cancer patients.
Ventafridda V; Ripamonti C; Caraceni A; Spoldi E; Messina L; De Conno F
Tumori; 1990 Aug; 76(4):389-93. PubMed ID: 1697993
[TBL] [Abstract][Full Text] [Related]
16. Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction.
Currow DC; Quinn S; Agar M; Fazekas B; Hardy J; McCaffrey N; Eckermann S; Abernethy AP; Clark K
J Pain Symptom Manage; 2015 May; 49(5):814-21. PubMed ID: 25462210
[TBL] [Abstract][Full Text] [Related]
17. Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review.
Mercadante S; Casuccio A; Mangione S
J Pain Symptom Manage; 2007 Feb; 33(2):217-23. PubMed ID: 17280927
[TBL] [Abstract][Full Text] [Related]
18. [Application of sandostatin in malignant bowel obstruction].
Li J; Jing ML; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2007 Sep; 10(5):479-81. PubMed ID: 17851794
[TBL] [Abstract][Full Text] [Related]
19. Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update.
Davis M; Hui D; Davies A; Ripamonti C; Capela A; DeFeo G; Del Fabbro E; Bruera E
Support Care Cancer; 2021 Dec; 29(12):8089-8096. PubMed ID: 34390398
[TBL] [Abstract][Full Text] [Related]
20. [A clinical study using octreotide in relieving gastrointestinal symptoms due to bowel obstruction in a terminally ill cancer patient].
Shima Y; Yamaguchi K; Miyata Y; Hyodo I; Yagi Y; Honke Y
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1377-82. PubMed ID: 15446560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
